RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer

Cancer

Volumn 121, Issue 8, 2015, Pages 1195-1203

  Yaeger, Rona ^a   Cowell, Elizabeth ^a   Chou, Joanne F ^a   Gewirtz, Alexandra N ^a   Borsu, Laetitia ^a   Vakiani, Efsevia ^a   Solit, David B ^a   Rosen, Neal ^a   Capanu, Marinela ^a   Ladanyi, Marc ^a   Kemeny, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

colorectal cancer; neoplasm metastasis; PIK3CA; prognosis; RAS

Indexed keywords

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER SURVIVAL; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; OVERALL SURVIVAL; PIK3CA GENE; PRIORITY JOURNAL; SURVIVAL PREDICTION; AGED; BONE TUMOR; BRAIN TUMOR; COLORECTAL TUMOR; GENETICS; LIVER TUMOR; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84927014631     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29196     Document Type: Article

References (29)

1. Fearon ER, Vogelstein B,. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-767.
2. Whitehall VL, Rickman C, Bond CE, et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer. 2012; 131: 813-820.
3. Zhao L, Vogt PK,. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008; 27: 5486-5496.
4. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001; 85: 692-696.
5. Imamura Y, Morikawa T, Liao X, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. 2012; 18: 4753-4763.
6. Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009; 27: 1477-1484.
7. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011; 117: 4623-4632.
8. Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014; 120: 2316-2324.
9. Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013; 119: 4137-4144.
10. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013; 258: 619-626; discussion 626-617.
11. Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014 [Epub ahead of print].
12. Arcila M, Lau C, Nafa K, Ladanyi M,. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn. 2011; 13: 64-73.
13. Janakiraman M, Vakiani E, Zeng Z, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010; 70: 5901-5911.
14. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30: 2956-2962.
15. Venook AP, Niedzwiecki D, Lenz H, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014; 32 (Ssuppl);Abstract LBA3.
16. Alden TD, Gianino JW, Saclarides TJ,. Brain metastases from colorectal cancer. Dis Colon Rectum. 1996; 39: 541-545.
17. Damiens K, Ayoub JP, Lemieux B, et al. Clinical features and course of brain metastases in colorectal cancer: an experience from a single institution. Curr Oncol. 2012; 19: 254-258.
18. Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ,. Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression. BMC Cancer. 2009; 9: 274.
19. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011; 17: 1122-1130.
20. Schluter K, Gassmann P, Enns A, et al. Organ-specific metastatic tumor cell adhesion and extravasation of colon carcinoma cells with different metastatic potential. Am J Pathol. 2006; 169: 1064-1073.
21. Urosevic J, Garcia-Albeniz X, Planet E, et al. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol. 2014; 16: 685-694.
22. Zheng Y, Xia Y, Hawke D, et al. FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell. 2009; 35: 11-25.
23. Zheng Y, Yang W, Xia Y, Hawke D, Liu DX, Lu Z,. Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylation-dependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol Cell Biol. 2011; 31: 4258-4269.
24. Kim JC, Crary B, Chang YC, Kwon-Chung KJ, Kim KJ,. Cryptococcus neoformans activates RhoGTPase proteins followed by protein kinase C, focal adhesion kinase, and ezrin to promote traversal across the blood-brain barrier. J Biol Chem. 2012; 287: 36147-36157.
25. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-762.
26. Karapetis CS, Jonker D, Daneshmand M, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014; 20: 744-753.
27. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer. 2010; 46: 1997-2009.
28. Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012; 18: 2257-2268.
29. Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013; 105: 1789-1798.